Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charlotte Becker

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
International Journal of Cancer|February 11, 2012
Prospectively measured thyroid hormones and thyroid peroxidase antibodies in relation to breast cancer riskAda Tosovic, Charlotte Becker, Anne-Greth Bondeson, et al.
Human Reproduction (Oxford, England)|January 14, 2011
Circadian variation in concentration of anti-Müllerian hormone in regularly menstruating females: relation to age, gonadotrophin and sex steroid levelsLeif Bungum, Anna-Karin Jacobsson, Fredrik Rosén, et al.
Proteomics. Clinical Applications|September 9, 2014
Identification of plasma protein profiles associated with risk groups of prostate cancer patientsMalin Nordström, Christer Wingren, Carsten Rose, et al.
Clinical Chemistry|December 31, 2005
Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-term storage at -20 degrees CDavid Ulmert, Charlotte Becker, Jan-Ake Nilsson, et al.
The Journal of Urology|November 25, 2003
Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsiesAlexander Haese, Markus Graefen, Thomas Steuber, et al.
Clinical Chemistry|February 19, 2005
Comparison of cardiac troponin I immunoassays variably affected by circulating autoantibodiesSusann Eriksson, Tuomo Ilva, Charlotte Becker, et al.
Bone|June 16, 2026
Childhood cancer survivors with premature ovarian insufficiency have low bone mineral density at long term follow-upAxel Netterlid, Helena Mörse, Kristina E Åkesson, et al.
Lakartidningen|October 27, 2012
[Equalis/SFKK recommends harmonization of units in hormone determinations for safer care]Göran Brattsand, Gunnar Nordin, Anders Isaksson, et al.
BMC Medicine|July 10, 2008
A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, SwedenAndrew J Vickers, Angel M Cronin, Gunnar Aus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2007
Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 yearsHans Lilja, David Ulmert, Thomas Björk, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
International Journal of Cancer|February 11, 2012
Prospectively measured thyroid hormones and thyroid peroxidase antibodies in relation to breast cancer riskAda Tosovic, Charlotte Becker, Anne-Greth Bondeson, et al.
Human Reproduction (Oxford, England)|January 14, 2011
Circadian variation in concentration of anti-Müllerian hormone in regularly menstruating females: relation to age, gonadotrophin and sex steroid levelsLeif Bungum, Anna-Karin Jacobsson, Fredrik Rosén, et al.
Proteomics. Clinical Applications|September 9, 2014
Identification of plasma protein profiles associated with risk groups of prostate cancer patientsMalin Nordström, Christer Wingren, Carsten Rose, et al.
Clinical Chemistry|December 31, 2005
Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-term storage at -20 degrees CDavid Ulmert, Charlotte Becker, Jan-Ake Nilsson, et al.
The Journal of Urology|November 25, 2003
Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsiesAlexander Haese, Markus Graefen, Thomas Steuber, et al.
Clinical Chemistry|February 19, 2005
Comparison of cardiac troponin I immunoassays variably affected by circulating autoantibodiesSusann Eriksson, Tuomo Ilva, Charlotte Becker, et al.
Bone|June 16, 2026
Childhood cancer survivors with premature ovarian insufficiency have low bone mineral density at long term follow-upAxel Netterlid, Helena Mörse, Kristina E Åkesson, et al.
Lakartidningen|October 27, 2012
[Equalis/SFKK recommends harmonization of units in hormone determinations for safer care]Göran Brattsand, Gunnar Nordin, Anders Isaksson, et al.
BMC Medicine|July 10, 2008
A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, SwedenAndrew J Vickers, Angel M Cronin, Gunnar Aus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2007
Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 yearsHans Lilja, David Ulmert, Thomas Björk, et al.
Pageof 4